Over-the-counter antihistamines in insomnia therapy
DOI:
https://doi.org/10.56782/pps.216Keywords:
antihistamines, diphenhydramine , doxylamine , allergy , insomniaAbstract
The initial antihistamines were introduced over eight decades ago and encompass two generations of H1 receptor antagonists. The initial generation of antihistamines, which possess an additional sedative effect, was employed in the treatment of insomnia. One of the antihistamines utilized in the treatment of insomnia is diphenhydramine. Despite its proven efficacy when administered orally, the drug has numerous side effects and contraindications. The use of this medication has been demonstrated to significantly exacerbate the effects of other pharmaceutical agents and may potentially lead to the development of dependence. Another substance with significant structural similarity to diphenhydramine and employed in medicinal products for the treatment of insomnia is doxylamine. It belongs to the first generation of H1 antihistamines and is of significant interest. It exhibits sedative, hypnotic, antiemetic and antihyperalgesic properties. The objective of this paper is to discuss histamine receptors, the effects of histamine, antihistamines and to present safe methods for the prevention and treatment of sleep disorders.
Downloads
References
1. Wazaify, M.; Elayehet E.; Tubeileh R.; Hammad, E.A. Assessing insomnia management in community pharmacy setting in Jordan: A simulated patient approach. PLoS One 2019, 14(12): e0226076. DOI: 10.1371/journal.pone.0226076 DOI: https://doi.org/10.1371/journal.pone.0226076
2. Rang, H.P.; Dale, M.M.; Ritter, J.M.; Flower, R.; Henderson, G. Farmakologia, Mirowska-Guzel, D.; Członkowski, A.; Okopień, B.; Edra Urban & Partner: Wrocław, Poland, 2012; pp. 23-25, 45, 251-252.
3. Mutschler, E.; Geisslinger G.; Kroemer H.K; Ruth, P. Farmakologia i toksykologia. Podręcznik, Droździk, M.; Kocić, I.; Pawlak, D.; MedPharm Polska: Wrocław, Poland, 2016; pp. 186-190.
4. Brzozowski, T. Konturek - Fizjologia Człowieka. Vol. III.; Edra Urban & Partner: Wrocław, Poland, 2019; pp. 21-25.
5. Silverthorn, D.U. Fizjologia człowieka. Zintegrowane podejście. Vol. I., Ponikowska, B.; PZWL Wydawnictwo Lekarskie: Warszawa, Poland, 2018; pp. 80-110.
6. Ganong, W.F. Fizjologia. Vol. I., Lewin-Kowalik, J.; PZWL Wydawnictwo Lekarskie: Warszawa, Poland, 2007; pp. 93-113.
7. Warren, C.M.; Jiang, J.; Gupta, R.S. Epidemiology and Burden of Food Allergy. Curr Allergy Asthma Rep. 2020, 20(2):6. DOI: 10.1007/s11882-020-0898-7 DOI: https://doi.org/10.1007/s11882-020-0898-7
8. Medycyna Praktyczna. https://www.mp.pl/pacjent/alergie/chorobyalergiczne/wartowiedziec/161009,histamina (data dostępu 18.02.2024).
9. Medycyna Praktyczna. https://www.mp.pl/pacjent/leki/subst.html?id=220 (data dostępu 17.11.2023).
10. Jędra, M. Histamina i inne aminy występujące w żywności. Roczniki PZH 1988, XXXIX:6.
11. Bajda, M.; Byrtus, H.; Chłoń-Rzepa, G. Chemia leków. Vol. I., Pawłowski, M.; PZWL Wydawnictwo Lekarskie: Warszawa, Poland, 2020; pp. 317-340.
12. Puls Medycyny. https://pulsmedycyny.pl/w-leczeniu-alergii-najwazniejsze-jest-bezpieczenstwo-pacjentow-982747 (data dostępu 05.03.2024).
13. Kawalec, A.; Pawlas, K. Czynniki środowiskowe wpływające na sen oraz zachowywanie higieny snu. Probl Hig Epidemiol. 2013, 94(1):1-5.
14. Vitale, K.C.; Owens, R.; Hopkins, S.R.; et al. Sleep Hygiene for Optimizing Recovery in Athletes: Review and Recommendations. Int J Sports Med 2019, 40(8):535–543. DOI: 10.1055/a-0905-3103 DOI: https://doi.org/10.1055/a-0905-3103
15. Charakterystyka produktu leczniczego, Optimum, tabletki uspokajające. https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/27156/characteristic (data dostępu 14.09.2024).
16. Charakterystyka Produktu Leczniczego, Melatonina LEK-AM. https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/9724/characteristic (data dostępu 14.09.2024).
17. Charakterytyka produktu leczniczego, Dorminox 12,5 mg, tabletki powlekane. https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/42445/characteristic (data dostępu 14.09.2024).
18. Charakterytyka produktu leczniczego, Luminastil, 50 mg, tabletki. https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/41556/characteristic (data dostępu 14.09.2024).
19. Janiec, W. Kompendium farmakologii. Vol. V.; PZWL Wydawnictwo Lekarskie: Warszawa, Poland, 2021; pp 334-342.
20. Nemanicha, A.; Liebeltb, E.; Sabbatini, A.K. Increased rates of diphenhydramine overdose, abuse, and misuse in the United States, 2005–2016. Clinical Toxicology 2021, 59(11):1002–1008. DOI: 10.1080/15563650.2021.1892716 DOI: https://doi.org/10.1080/15563650.2021.1892716
21. Charakterytyka Produktu Leczniczego, Senamina, 12,5 mg, tabletki powlekane. https://rejestrymedyczne.ezdrowie.gov.pl/api/rpl/medicinal-products/41940/characteristic (data dostępu 14.09.2024).
22. Brott, N.R.; Reddivari, A.K.R. Doxylamine. StatPearls Publishing 2024, ID: NBK551646
23. Zimmerman, J.T.; Schreiber, S.J.; Huddle, L.N. Case Report of Lethal Concentrations of the Over-the-Counter Sleep Aids Diphenhydramine and Melatonin. Am J Forensic Med Pathol. 2023, 44(3):227-230. DOI: 10.1097/PAF.0000000000000833 DOI: https://doi.org/10.1097/PAF.0000000000000833
24. Charakterytyka produktu leczniczego, Apap noc, 500 mg + 25 mg, tabletki powlekane. http://chpl.com.pl/data_files/2012-06-21_ApapNoc_ChPL.pdf (data dostępu 14.09.2024).
25. Mohan, S.; Backus, T.; Furlano, E.; et al. A Case of Massive Diphenhydramine and Naproxen Overdose. J. Emerg. Med. 2021, 61(3):259-264. DOI: 10.1016/j.jemermed.2021.04.020 DOI: https://doi.org/10.1016/j.jemermed.2021.04.020
26. Ali, Z.; Khan, M.; Ullah, W.; Kpehor, A.A.; Cheema, M.A. QT interval prolongation and rhabdomyolysis associated with diphenhydramine toxicity: a case report. J Community Hosp Intern Med Perspect 2020, 10(2):151-153. DOI: 10.1080/20009666.2020.1749511 DOI: https://doi.org/10.1080/20009666.2020.1749511
27. Shah, A.; Yousuf, T.; Ziffra, J.; Zaidi, A.; Raghuvir, R. Diphenhydramine and QT prolongation - A rare cardiac side effect of a drug used in common practice. J Cardiol Cases 2015, 12(4):126-129. DOI: 10.1016/j.jccase.2015.06.002 DOI: https://doi.org/10.1016/j.jccase.2015.06.002
28. Poluzzi, E.; Raschi, E.; Godman, B.; Koci, A.; Moretti, U.; Kalaba, M.; Wettermark, B.; Sturkenboom, M.; De Ponti, F.. Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across Europe. PLoS One 2015, 10(3):e0119551. DOI: 10.1371/journal.pone.0119551 DOI: https://doi.org/10.1371/journal.pone.0119551
29. Ramakrishna, K.N.; Shah, A; Martinez-Balzano, C.D. Massively elevated creatine kinase levels in antihistamine-induced rhabdomyolysis. Proc (Bayl Univ Med Cent) 2020, 33(1):44-46. DOI: 10.1080/08998280.2019.1688624 DOI: https://doi.org/10.1080/08998280.2019.1688624
30. Cadet, B.; Bhutta, S.; Mahmoudzadeh, S.; Merisier, M.; Shah, N. When Overdose of Doxylamine Leads to Severe Rhabdomyolysis and Renal Failure That Requires Hemodialysis: A Case Report and Literature Review. Cureus 2023, 15(8):e43395. DOI: 10.7759/cureus.43395 DOI: https://doi.org/10.7759/cureus.43395
31. Jo, Y.I.; Song, J.O; Park, J.H; Koh, S.Y.; Lee, S.M.; Seo, T.H.; Lee, J.H. Risk factors for rhabdomyolysis following doxylamine overdose. Hum Exp Toxicol 2007, 26(8):617-21. DOI: 10.1177/0960327107077507 DOI: https://doi.org/10.1177/0960327107077507
32. Syed, H.; Som, S.; Khan, N.; Faltas, W. Doxylamine toxicity: seizure, rhabdomyolysis and false positive urine drug screen for methadone. BMJ Case Rep 2009, 2009:bcr09.2008.0879. DOI: 10.1136/bcr.09.2008.0879 DOI: https://doi.org/10.1136/bcr.09.2008.0879
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Patrycja Słomczyńska, Jakub Młoźniak, Katarzyna Paradowska
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
